A: EraGen was founded in 1994 as Sulfonics, Inc., a California corporation. It changed its name to EraGen Biosciences and was reincorporated in Delaware in 1999. In 2002 the company consolidated its operations from Florida to new facilities in Madison, Wisconsin.
Q: How large is EraGen?
A: EraGen is a relatively small corporation, currently employing over 40 individuals in Madison, Wisconsin. The company continues to grow and anticipates increasing the number of employees and manufacturing facilities over the next two years.
Q: What are the company's goals?
A: EraGen will continue efforts to drive value by developing quality products for essential molecular diagnostics, building long term partnerships with industry leaders and creating a best-in-class Company.
Q: What are EraGen's proprietary technology and products?
A: EraGen has two major product lines under the brand name MultiCode that are powered by the company's core patented chemistry technology, the expanded genetic alphabet. These product lines include a multiplexed quantitative chemistry for real-time analysis (MultiCode-RTx System) and a high throughput multiplexed array system (MultiCode-PLx System).
Q: Who are EraGen's major partners?
A: Notable relationships include Bayer HealthCare in the area of molecular diagnostics, a long standing partner with EraGen. EraGen technology is at the core of Bayer's Versant Line of Infectious Disease bDNA Diagnostic Tests. Recently the two companies co-developed an innovative cystic fibrosis test. In the life science research market, EraGen holds a close relationship with Promega Corporation, who is licensed to market and sell EraGen quantitative real-time chemistry and annalysis software under the PlexorÔ brand name.
Q: What is the status of EraGen intellectual property?
A: EraGen holds 12 issued U.S. Patents in the areas of nucleic acid chemistry, proteomics and drug synthesis.
